Aurinia Pharmaceuticals Inc (AUPH)vsMerck & Company Inc (MRK)
AUPH
Aurinia Pharmaceuticals Inc
$15.72
+3.22%
HEALTHCARE · Cap: $2.02B
MRK
Merck & Company Inc
$111.28
-0.09%
HEALTHCARE · Cap: $277.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21948% more annual revenue ($65.77B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 13.6%. AUPH trades at a lower P/E of 7.3x. AUPH earns a higher WallStSmart Score of 69/100 (B-).
AUPH
Strong Buy69
out of 100
Grade: B-
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
-13.8%
Fair Value
$97.84
Current Price
$111.28
$13.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 65 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Distress zone — elevated risk
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AUPH
The primary concerns for AUPH are Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AUPH profiles as a growth stock while MRK is a value play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.45 — expect wider price swings.
AUPH is growing revenue faster at 24.4% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (69/100 vs 50/100), backed by strong 100.0% margins and 24.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?